Younger RJ, Knopp EA. Mind MRI: tumor analysis. J Magn Reson Imaging. 2006;24(4):709–24.
Cheng W, Ping Y, Zhang Y, Chuang KH, Liu Y. Magnetic resonance imaging (MRI) distinction brokers for tumor prognosis. J Healthc Eng. 2013;4(1):23–45.
Zhou Z, Lu ZR. Gadolinium-based distinction brokers for magnetic resonance most cancers imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(1):1–18.
Kanal E, Tweedle MF. Residual or retained gadolinium: sensible implications for radiologists and our sufferers. Radiology. 2015;275(3):630–4.
Beam AS, Moore KG, Gillis SN, Ford KF, Grey T, Steinwinder AH, et al. GBCAs and threat for nephrogenic systemic fibrosis: a literature evaluate. Radiol Technol. 2017;88(6):583–9.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based distinction agent accumulation and toxicity: an replace. AJNR Am J Neuroradiol. 2016;37(7):1192–8.
Guo BJ, Yang ZL, Zhang LJ. Gadolinium deposition in mind: present scientific proof and future views. Entrance Mol Neurosci. 2018;20(11):335.
Oliveira AC, Filipe HAL, Ramalho JPP, Salvador A, Geraldes CFGC, Moreno MJ, et al. Modeling Gd3+ complexes for molecular dynamics simulations: towards a rational optimization of MRI distinction brokers. Inorg Chem. 2022;61(30):11837–58.
Trattnig S, Pinker Okay, Ba-Ssalamah A, Nöbauer-Huhmann IM. The optimum use of distinction brokers at excessive area MRI. Eur Radiol. 2006;16(6):1280–7.
Hagberg GE, Scheffler Okay. Impact of r1 and r2 relaxivity of gadolinium-based distinction brokers on the T1-weighted MR sign at rising magnetic area strengths. Distinction Media Mol Imaging. 2013;8(6):456–65.
Noebauer-Huhmann IM, Szomolanyi P, Kronnerwetter C, Widhalm G, Weber M, Nemec S, et al. Mind tumors at 7T MRI in comparison with 3T–distinction impact after half and full commonplace distinction agent dose: preliminary outcomes. Eur Radiol. 2015;25(1):106–12.
Krautmacher C, Willinek WA, Tschampa HJ, Born M, Träber F, Gieseke J, et al. Mind tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T in contrast with 1.5 T-initial expertise. Radiology. 2005;237(3):1014–9.
Vaughan JT, Snyder CJ, DelaBarre LJ, Bolan PJ, Tian J, Bolinger L, et al. Entire-body imaging at 7T: preliminary outcomes. Magn Reson Med. 2009;61(1):244–8.
Yetisir F, Poser BA, Grant PE, Adalsteinsson E, Wald LL, Guerin B. Parallel transmission 2D RARE imaging at 7T with transmit area inhomogeneity mitigation and native SAR management. Magn Reson Imaging. 2022;93:87–96.
Shi Z, Zhao X, Zhu S, Miao X, Zhang Y, Han S, et al. Time-of-flight intracranial MRA at 3 T versus 5 T versus 7 T: visualization of distal small cerebral arteries. Radiology. 2022;30:220114.
Aja-Fernández S, Vegas-Sánchez-Ferrero G, Tristán-Vega A. Noise estimation in parallel MRI: GRAPPA and SENSE. Magn Reson Imaging. 2014;32(3):281–90.
Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI distinction brokers: primary chemistry and security. J Magn Reson Imaging. 2012;36(5):1060–71.
The pharmacokinetic properties of Gadobutrol. https://www.bayer.com/websites/default/information/GADOVIST_EN_PI.pdf.
Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–50.
Shen Y, Goerner FL, Snyder C, Morelli JN, Hao D, Hu D, et al. T1 relaxivities of gadolinium-based magnetic resonance distinction brokers in human complete blood at 1.5, 3, and seven T. Make investments Radiol. 2015;50(5):330–8.
Kalavagunta C, Michaeli S, Metzger GJ. In vitro Gd-DTPA relaxometry research in oxygenated venous human blood and aqueous answer at 3 and seven T. Distinction Media Mol Imaging. 2014;9(2):169–76.
Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparability of magnetic properties of MRI distinction media options at completely different magnetic area strengths. Make investments Radiol. 2005;40(11):715–24.
Parikh PT, Sandhu GS, Blackham KA, Coffey MD, Hsu D, Liu Okay, Jesberger J, Griswold M, Sunshine JL. Analysis of picture high quality of a 32-channel versus a 12-channel head coil at 1.5T for MR imaging of the mind. AJNR Am J Neuroradiol. 2011;32(2):365–73.
Albrecht J, Burke M, Haegler Okay, Schöpf V, Kleemann AM, Paolini M, Wiesmann M, Linn J. Potential affect of a 32-channel receiving head coil know-how on the outcomes of a purposeful MRI paradigm. Clin Neuroradiol. 2010;20(4):223–9.
Pacioni S, D’Alessandris QG, Buccarelli M, Boe A, Martini M, Larocca LM, et al. Mind invasion alongside perivascular areas by glioma cells: relationship with blood-brain barrier. Cancers (Basel). 2019;12(1):18.
Kakeda S, Korogi Y, Hiai Y, Ohnari N, Moriya J, Kamada Okay, et al. Detection of mind metastasis at 3T: comparability amongst SE, IR-FSE and 3D-GRE sequences. Eur Radiol. 2007;17(9):2345–51.
Collins CM, Smith MB. Sign-to-noise ratio and absorbed energy as features of primary magnetic area power, and definition of “90 levels ” RF pulse for the top within the birdcage coil. Magn Reson Med. 2001;45(4):684–91.
Kim KN, Hernandez D, Website positioning JH, Noh Y, Han Y, Ryu YC, et al. Quantitative evaluation of phased array coils with completely different numbers of receiving channels by way of signal-to-noise ratio and spatial noise variation in magnetic resonance imaging. PLoS ONE. 2019;14(7):e0219407.
Fushimi Y, Miki Y, Urayama S, Okada T, Mori N, Hanakawa T, et al. Grey matter-white matter distinction on spin-echo T1-weighted photos at 3 T and 1.5 T: a quantitative comparability research. Eur Radiol. 2007;17(11):2921–5.
Brink WM, Webb AG. Excessive permittivity pads scale back particular absorption fee, enhance B1 homogeneity, and improve contrast-to-noise ratio for purposeful cardiac MRI at 3 T. Magn Reson Med. 2014;71(4):1632–40.
Vaughan JT, Garwood M, Collins CM, Liu W, DelaBarre L, Adriany G, et al. 7T vs. 4T: RF energy, homogeneity, and signal-to-noise comparability in head photos. Magn Reson Med. 2001;46(1):24–30.
Manning C, Stringer M, Dickie B, Clancy U, Valdés Hernandez MC, Wiseman SJ, et al. Sources of systematic error in DCE-MRI estimation of low-level blood-brain barrier leakage. Magn Reson Med. 2021;86(4):1888–903.
Ochi T, Taoka T, Matsuda R, Sakamoto M, Akashi T, Tamamoto T, et al. Comparability between two separate injections and a single injection of double-dose distinction medium for contrast-enhanced MR imaging of metastatic mind tumors. Magn Reson Med Sci. 2014;13(4):221–9.
Koenig M, Schulte-Altedorneburg G, Piontek M, Hentsch A, Spangenberg P, Schwenke C, et al. Intra-individual, randomised comparability of the MRI distinction brokers gadobutrol versus gadoteridol in sufferers with major and secondary mind tumors, evaluated in a blinded learn. Eur Radiol. 2013;23(12):3287–95.
